humans with NPC1 disease (13, 14) . How this apoptotic program is activated in NPC disease is still not known; however, an early step in this pathway is the transcriptional activation of proapoptotic genes such as BH3-only proteins Noxa, Puma, and Bax (15) . In addition, accumulation of glycolipids and cholesterol in lysosomes-as it is observed in NPC brains-activates oxidative stress and endoplasmic reticulum (ER) stressinduced apoptosis (16 -19) .
Growing evidence indicates that the p53 family of transcription factors, mainly its p73 member, determines neuronal life vs. death (20) . The p73 transcription factor induces the expression of many proapoptotic genes (including the BH3-only proteins and the ER stress-related-protein Scotin) that finally leads to caspase activation (20, 21) . Phosphorylation by c-Abl kinase is the main upstream mechanism that regulates p73 protein levels by stabilization (22) . c-Abl activation and autophosphorylation are induced by DNA damage, oxidative stress, ER stress, and other types of cell damage (23) . p73 is also associated with apoptosis induced by DNA damage (24) and participates in ER stress-induced apoptosis (21) .
Previous studies in our laboratory supported the idea that the c-Abl/p73 pathway has a major role in neuronal death. We found that A␤ fibrils (amyloid) and oxidative stress increase c-Abl activity in rat hippocampal neurons and enhance the interaction of p73 with c-Abl as well as the nuclear translocation of p73 (25) .
The relation between NPC neurodegeneration and the activation of the apoptotic system c-Abl/p73 has not been explored. To study this possibility we analyzed the presence of the c-Abl/p73 system in the cerebellum, one of the brain regions that is most affected in NPC brains. We found that both c-Abl and p73 proteins are expressed in cerebellum. In NPC mice the cerebellar expression of the proapoptotic phosphorylated p73 colocalized with c-Abl and active caspase-3 in Purkinje cells, and p73-proapoptotic target genes levels are increased. Strikingly, inhibition of the c-Abl kinase with imatinib mesylate (STI571) reduces weight loss, neurological symptoms, and cerebellar apoptosis, increasing the number of Purkinje cells and survival of NPC mice. Our results support the hypothesis that the c-Abl/p73 pathway is involved in NPC neurodegeneration and show that treatment with c-Abl inhibitors is useful in ameliorating progression of the disease.
MATERIALS AND METHODS

Mice
BALB/c mice carrying a heterozygous mutation in the npc1 gene were kindly donated by Dr. Peter Pentchev (U.S. National Institutes of Health, Bethesda, MD, USA). Genotypes were identified using polymerase chain reaction (PCR) -based screening as described previously (26) . Animal protocols were reviewed and approved by the animal studies review board at our institution.
Imatinib treatment
Mice received daily intraperitoneal injections of imatinib mesylate (Gleevec; Novartis, Basel, Switzerland) (5 mg/kg in 0.9% NaCl) from postnatal day (p) 7 or 28. Control groups (wild-type and NPC) received daily intraperitoneal injections of 0.9% NaCl.
Locomotor testing
The investigator was masked to the genotype and treatment group. Locomotor coordination was evaluated weekly by two tests during imatinib treatment. In the hanging test, the mouse was placed to hang at the center of a horizontal bar (3 mm diameter; 35 mm long) with forepaws. The body position of the animal was observed for 30 s and scored as described in Võikar et al. (27) . In the beam test mice were placed at the end of a beam (100 cm long; 2.5 cm wide). Animals were trained to finish the task as quickly as possible. The number of falls during the test was counted. Footprint analysis was performed in imatinib-treated animals from p28 at 8 wk of age, as described previously (28) .
Histological analysis
Cerebellar sections from 4% paraformaldehyde fixed brains were cut into 40-m slices and analyzed as follows.
Immunohistochemical procedures
Anti-calbindin D-28K (AB1778, 1:1000; Chemicon International, Temecula, CA, USA), GM2 (ab23942, 1:100; Abcam, Cambridge, UK), and anti-CD11b (5C6, 1:100; Serotec, Oxford, UK) were used with the avidin-biotin-horseradish peroxidase complex method (Vector Laboratories, Burlingame, CA, USA).
Immunofluorescence
Sections to measure immunofluorescence were incubated overnight with anti-rabbit p73 polyclonal (H79, 1:250; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), anti-mouse monoclonal c-Abl (24-11, 1:250; Santa Cruz Biotechnology, Inc.), anti-rabbit phosphop73 (Tyr99; 1:100; Cell Signaling Technology Inc., Danvers, MA, USA), anti-rabbit phospho-c-Abl (Tyr412, 1:250; Sigma-Aldrich, St. Louis MO, USA), anti-mouse p73 (IMG-246, 1:250; IMGENEX, San Diego, CA, USA), anti-rabbit calbindin (AB1778, 1:1000; Chemicon, Harrow, UK), anti-rabbit caspase-3-active (1:200; Chemicon International), and anti-glial fibrillary acidic protein (GFAP) (1:200; Chemicon International) antibodies. Secondary antibodies conjugated with anti-mouse Alexa Fluor-488 or anti-rabbit Alexa Fluor-594 were used at 1:1000 dilution (Molecular Probes, Eugene, OR, USA). In some cases, the sections were used for terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assays.
slides, and covered with Fluoromount-G (SouthernBiotech, Birmingham, AL, USA). Fluorescent images were captured with a confocal Olympus microscope and with an Olympus BX51 microscope (Olympus, Tokyo, Japan) and analyzed with Image-Pro Express (Media Cybernetics, Bethesda, MD, USA).
Western blot analysis
Tissue proteins were prepared as described previously (16) . Cerebellum protein samples (50 g) were resolved with SDS-PAGE. Rabbit p73 (H-79, 1:1000; Santa Cruz Biotechnology, Inc.), phospho-p73 (Tyr99, 1:1000 dilution), and antimouse tubulin (dilution 1:5000; Sigma-Aldrich) antibodies and secondary antibodies conjugated with horseradish peroxidase (dilution 1:3000; Upstate Biotechnology, Lake Placid, NY) were used.
In situ apoptosis detection
The TUNEL assay was performed using an apoptosis detection kit purchased from Roche Molecular Biochemicals (Mannheim, Germany), following the manufacturer's instructions.
Real-time PCR analysis
Total RNA was extracted from cerebellum, pretreated with DNase (Invitrogen, Carlsbad, CA, USA), and then reversetranscribed to cDNA using random primers (Invitrogen). Real-time PCR was performed using a LightCycler FastStart DNA Master SYBR Green I kit (Roche, Basel, Switzerland). The PCR conditions and the gene-specific primer sequence are included as Supplemental Data. Data from the PCR reactions were analyzed using the mathematical model described by Pfaffl (29) .
Statistical analysis
Mean Ϯ se values for the number of experiments are indicated in the figure legends. To obtain the P value, Student's t test was performed on the data using Sigma Plot 2004 (version 9.0; Systat Software Inc., Chicago, IL, USA).
RESULTS
Expression and activation of the c-Abl/p73 system in the cerebellums of NPC mice
To explore the connection between the c-Abl/p73 proapoptotic pathway and NPC neurodegeneration, we first analyzed the cerebellar distribution of c-Abl and p73 proteins by immunofluorescence in wild-type and NPC mice (8-wk-old mice). NPC animals showed an increased number of cells positive for p73 and c-Abl proteins compared with the same area in wild-type animals (Fig. 1A, B) . We observed colocalization of c-Abl and p73 signals in NPC cerebellums (Fig. 1A) . In addition, some cells of the NPC mice showed apoptotic morphologies, with a strong p73 signal (Fig. 1A) . In NPC tissues, the p73-positive cells were found in Purkinje and granular layers (arrows in Fig. 1A) , and in the molecular layer (arrowheads in Fig. 1A ). The GFAP signal does not colocalize with the p73 signal, indicating that these p73-positive cell bodies in the molecular layer are not astrocytes (Supplemental Fig. 1, merge) .
We then evaluated the expression of the phosphorylated and activated forms of c-Abl and p73, P-cAbl and P-p73, respectively (Fig. 1C ). We found a dramatic difference between wild-type and NPC cerebellums, with clearly positive cells for both phosphorylated proteins only in NPC mice (Fig. 1D) . Supplemental Fig. 2 shows the expression and colocalization of the pairs P-cAbl, p73 and P-p73, c-Abl. We found that signals for all of these proteins were increased and colocalized in NPC mice.
Next, we analyzed colocalization of p73 with calbindin, a specific Purkinje neuron marker in NPC cerebellums. We found that most of the Purkinje cells with apoptotic appearance (small and condensed nuclei and small prolongations) were also p73-positive, and some with clearly apoptotic nuclei positive for both signals were visualized (arrows, Fig. 1E ). The surviving Purkinje cells, which were apparently healthy, were negative for p73 (arrowhead, Fig. 1E ). We found an increase in activated caspase-3 in NPC brain (Fig. 1E, F ) and most caspase-3-positive cells were also positive for p73. Supplemental Fig. 3 shows the analysis of larger cerebellar regions for p73, calbindin, and activated caspase-3 that confirms the previously described results, with most apoptotic Purkinje cells positive for p73 and caspase-3 and the surviving Purkinje cells negative for p73.
To corroborate the activation of the c-Abl/p73 pathway in NPC cerebellum, we then analyzed P-p73 and p73 protein levels by Western blot ( Fig. 2A) and the mRNA levels of the p73 proapoptotic target genes NOXA and Scotin by quantitative PCR (Fig. 2B ). We found increased protein levels of the phosphorylated p73 form and increased mRNA levels of NOXA and Scotin in NPC mice (Fig. 2B ).
These results, showing an increase in total and phosphorylated c-Abl and p73 levels in the cerebellums of NPC mice associated with caspase-3 activation and increased levels of p73 target genes, suggest in vivo activation of the c-Abl/p73 signal pathway in NPC disease.
Imatinib therapy decreases cerebellar mRNA expression levels of p73 target genes
The proapoptotic functions of p73 and the c-Abl/p73 system in neurodegeneration depend on c-Abl activity (25) . To assess the relevance of the c-Abl/p73 pathway in NPC neuron apoptosis and degeneration in vivo, we treated 4-wk-old NPC mice with the c-Abl inhibitor imatinib. We administered the drug by intraperitoneal injection over 28 days in a daily dose of 5 mg/kg and evaluated the consequences of imatinib administration on the NPC phenotype.
First, we tested whether imatinib administration reduced mRNA levels of NOXA and Scotin in normal and NPC mice. We found a significant decrease in the mRNA levels of NOXA and Scotin in cerebellums of normal and imatinib-treated NPC mice (Fig. 2C,  D) , in agreement with a p73 function dependent on c-Abl activity in NPC disease. As expected, free cholesterol and ganglioside accumulation was not affected in cerebellums of imatinib treated NPC mice (Supplemental Fig. 4 ). Because neurodegeneration in NPC disease is accompanied by inflammation, we measured the expression of the microglial cell inflammatory marker CD11b in imatinib-treated NPC 
Imatinib therapy improves locomotor function in NPC mice
Next, we analyzed the effect of imatinib on the life span of NPC mice, starting the treatment from p7 or p28. Imatinib treatment significantly improved survival of NPC mice by 12% when treatment started at p7; although a trend in this direction was observed if treatment started later, at p28, it was not statistically significant (Fig. 3A, B) .
Administration of imatinib delayed loss of weight in the NPC mice (Fig. 3C) . Weight started to decline at 7 wk in both untreated and imatinib-treated NPC mice from p7 and p28, but the rate of decline was reduced in imatinib-treated NPC mice (Fig. 3C) . Earlier administration of imatinib seemed to give better results, but there was no significant difference between the gain of weight curves of NPC mice treated from p7 or p28 (Fig.  3C ). There was no difference in the weight gain between imatinib-treated and untreated wild-type mice (data not shown).
We evaluated coordination and locomotor function using two different tests (Fig. 3D-F) at regular intervals throughout treatment. The imatinib-treated NPC mice exhibited a significant improvement in the hanging test, which evaluates coordination of the four paws and the tail (Fig. 3D) . A delay in the onset of symptoms was observed in p28 and p7 imatinib-treated mice from 7 and 8 wk, respectively. In the beam test, which evaluates equilibrium and coordination, the imatinib-treated NPC mice showed fewer falls than untreated NPC mice (Fig. 3E-F) . In this test, improvement was observed from 6 wk for both p7 and p28 imatinib-treated mice. We also evaluated the footprint pattern of treated animals from p28. In this test, imatinib-treated NPC mice showed a significant improvement compared with untreated NPC mice (Supplemental Fig. 6 ).
Although we did not find a significant difference in locomotor function between NPC mice receiving imatinib treatment from p7 and p28, we observed, as was shown previously, an increase in survival of mice in the p7 imatinib-treated group. This increase in survival correlates with a tendency toward greater corporal weight.
Imatinib therapy increases survival of Purkinje neurons and inhibits cerebellar apoptotic cell death in NPC mice
Because imatinib treatments from both p7 and p28 improved neurological function in the NPC mice at similar levels, we examined the effect of imatinib therapy on survival of cerebellar Purkinje cells in mice treated at p28. Imatinib treatment substantially improved Purkinje cell survival in NPC mice (Fig. 4) . The greatest loss of Purkinje cells occurs in cerebellar lobes 2 and 4, in which the imatinib treatment improved Purkinje cell survival from 10 to 44% and from 15 to 51%, respectively (Fig. 5) . In addition, imatinib treatment dramatically reduced the number of TUNEL-positive cells in NPC mice cerebellums at 8 wk of age (Fig. 5) . At this same age, untreated NPC mice had higher levels of TUNEL-positive cells in both granular and molecular layers of the cerebellum. A significant decrease in apoptotic cells with imatinib treatment in lobes 2 (Pϭ0.0003) and 4 (Pϭ0.019) correlated with an increase in calbindin staining in the same slices (Fig. 5) .
All of these results clearly show that imatinib treatment in NPC mice inhibits the cerebellar c-Abl/p73 transduction pathway, decreasing apoptosis and neurodegeneration, which leads to a delay in the loss of motor function and body weight, and increasing numbers of Purkinje cells and survival of NPC mice.
DISCUSSION
These data suggest that c-Abl and p73 play a role in cerebellar NPC neurodegeneration and that Purkinje neuronal loss in NPC brains can be counteracted with imatinib. The major findings of this work are the following: 1) apoptosis is a relevant mechanism leading to Purkinje cell death in NPC disease, corroborating earlier reports; 2) the c-Abl/p73 system and p73 proapoptotic target genes are expressed in the cerebellums of NPC mice; 3) the inhibition of c-Abl with the specific drug imatinib increases Purkinje cell survival and reduces apoptosis in the cerebellums of NPC mice, and concomitantly, imatinib reduces body weight loss, improves neurological symptoms of NPC mice, and increases survival of NPC mice; and 4) the prosurvival effect of imatinib is correlated with a decrease in mRNA levels of p73 proapoptotic target genes, supporting the idea that the effects of imatinib are mainly related to p73 signaling downstream of c-Abl.
Apoptosis is a relevant mechanism leading to Purkinje cell death in NPC disease
Our work represents the first demonstration that inhibition of apoptosis provides neuroprotection in the NPC1 mouse model. Previous studies have shown that NPC neurodegeneration is associated with an increase in apoptotic markers in brains of NPC1 Ϫ/Ϫ mice and humans with NPC1 disease (13) . In addition, it was shown that loss of Purkinje cells is primarily a cell autonomous defect in the mouse model of NPC (30) . Our results also show high levels of apoptosis in the NPC cerebellum with active caspase-3 and TUNEL-positive cells. However, previous studies using antiapoptotic strategies for stopping neuronal death in NPC mice have not been successful. Erickson and Bernard (31) showed no effect on cell death and neurological symptoms in NPC mice cross-bred with Bcl-2-overexpressing transgenic mice or after treatment with minocycline. Both Bcl-2 and minocycline inhibit caspase-1 activation, and minocycline protects against neuronal apoptosis in other mouse models of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD) (32, 33) . Failure to ameliorate neurodegeneration in these experiments in NPC mice may indicate that there are redundant mechanisms leading to apoptosis in NPC brain. Imatinib therapy increases survival and improves locomotor function of NPC mice. Imatinib (5 mg/kg in 0.9% NaCl) was given intraperitoneally to the mice in daily injections starting at p7 and p28. Survival was determined [NPC saline (sal) p7, nϭ6; NPC imatinib (imat) p7, nϭ7; NPC saline p28, nϭ5; and NPC imatinib p28, nϭ6] by continuing with the treatment until death (A, B) . Weight was registered during the full period of treatment (C). Motor coordination was assessed weekly by the hanging test (D) and the beam test (E). Data are means Ϯ se; 6 mice/group. *P Ͻ 0.05.
Expression and activation of c-Abl and p73 in Purkinje neurons in the cerebellums of NPC mice
p73 has been reported previously in the telencephalon (34), adult cortex, and hippocampus (35) . We also found increases in c-Abl, p73, and phosphorylated c-Abl and p73 forms in cerebellums of NPC mice, and these correlated with an increase in p73 target gene expression. Moreover, p73 signals were associated with active caspase-3 and apoptotic Purkinje cells. These results allow us to conclude that the c-Abl/p73 system is activated in NPC neurons, leading to neurodegeneration.
How the c-Abl/p73 pathway is activated in NPC disease is still not clear. NPC1
Ϫ/Ϫ deficiency has been shown to affect oxidative stress and calcium homeostasis (19) , both of which are potent c-Abl activators (23, 25) . Results obtained in vitro in neurons exposed to U18666A, a cellular model of NPC, and in NPC mouse brains show mitochondrial dysfunction and ATP deficiency, findings that are in accordance with the presence of oxidative stress in NPC disease (36, 37) . In addition, treatments with the antioxidants vitamin E and tamoxifen show a delay of symptoms in the mouse model of NPC disease (38) . Moreover, recent results obtained with global gene expression profiling show that NPC fibroblasts exhibit a gene expression profile indicative of oxidative stress (19) .
Supporting the role of c-Abl/p73 in neurodegeneration, we have reported that the c-Abl/p73 pathway is involved in hippocampal neuronal cell death induced by amyloid fibrils and oxidative stress (25) . Interestingly, p73 accumulates in the nucleus of neurons and colocalizes with neurofibrillary tangles in Alzheimer's disease (AD) brains (39) . Although the etiology of Alzheimer's disease and NPC diseases are probably different, amyloid peptide accumulation vs. lipid trafficking alteration and accumulation, they both share several neuropathological characteristics. Among them are neuronal degeneration, extensive growth of new ectopic dendrites, synaptic loss, and the appearance of dystrophic neuritis, as well as the formation of neurofibrillary tangles. Also, there are cytoskeletal abnormalities, with an increase in activity of the cyclin-dependent kinase 5 and tau hyperphosphorylation (40) .
In addition to NPC disease, cell death through apoptosis is considered to be an important pathological mechanism in a number of neurodegenerative disorders, such as AD, HD, and ALS, and also in lysosomal storage disorders, such as Sandhoff disease and TaySachs disease (41, 42) . Recently, it was shown that p73 is activated in striatal neurons of patients with HD (43) and in motor neurons of an ALS mouse model (44) . Therefore, it is possible that the activation of the c-Abl/p73 module is a common pathological mechanism participating in all of the above-mentioned diseases. This possibility deserves further investigation.
Imatinib treatment for NPC disease
The third and most relevant finding of our study is that imatinib treatment increased the quality of life of NPC mice by delaying body weight loss and neurological symptoms, decreasing cerebellar apoptosis and inflammation, and increasing Purkinje cell survival. These data support the idea that c-Abl activity may be involved in cell signals that regulate neuronal death and suggest that inhibition of the c-Abl/p73 module is an interesting therapeutic target in this disease and perhaps in other neurological disorders as well. Interestingly, imatinib (Gleevec, STI571) is a U.S. Food and Drug Administration-approved drug used in patients with chronic myelogenous leukemia, in which the therapeutic target is the aberrant oncogenic fusion protein Bcr-Abl (45, 46) .
Other c-Abl-independent mechanisms for the imatinib effect delaying locomotor symptoms in NPC mice cannot be ruled out. Recently it was shown that imatinib induces the cellular autophagy machinery in mammalian cells (47) . Autophagy is clearly induced in NPC disease (30, 48, 49) . As has been extensively discussed in the literature, autophagic activity can be protective under certain conditions, whereas it may lead to cell death under others (50, 51) . Further studies are required to determine whether imatinib induces more autophagy in NPC disease and if this contributes to the drug's beneficial effects on NPC mice. Also, we cannot eliminate the possibility that other targets of imatinib, such as c-Kit and platelet-derived growth factor receptor (52, 53) , could modulate the effects of imatinib in vivo, although both are prosurvival pathways, and their inhibition would probably enhance apoptosis and not prevent it (54 -56) . However, data presented here and additional data obtained by our laboratory suggest that the main target of imatinib in neurons is c-Abl. For example, administration of the drug significantly reduced the expression of p73 proapoptotic target genes in the cerebellums of wild-type and NPC mice. In addition, the neuronal cell death induced by A␤ fibrils could be prevented with imatinib and by the inhibition of c-Abl expression by RNA interference (25) . However, additional evidence for the requirement of c-Abl in apoptotic neuron death in NPC is required.
Although the imatinib treatment starting at 4 wk of age had beneficial effects on body weight loss and neurological symptoms and decreased cerebellar apoptosis, it did not show an effect on survival of NPC mice. However, earlier treatment with imatinib, before the onset of neuron degeneration (at p7) had a modest but clear positive effect on survival of NPC mice. In this regard, we note that treatment with the neurosteroid allopregnanolone (Allo) increases survival only when it is administered at very early stages, before p23, with a major improvement at p7, in NPC mice (57) . The hippocampus and the ventral posterior lateral and medial nuclei of the thalamus are also affected in NPC brain (12) , suggesting that other brain areas besides the cerebellum are responsible for death of NPC mice. In some of these cerebral regions apoptosis and the expression of p73 has not been described. Thus, it is possible that apoptosis and/or the c-Abl/p73 pathway do not play a relevant role in neurodegeneration in other brain regions known to be affected in NPC disease. Two other limitations for imatinib as a treatment in NPC are the limited penetration of the drug into the CNS, as it has been estimated that only 10% of the systemic drug reaches the CNS (58) and a cardiotoxic undesirable side effect (59) . Further studies with intraventricular administration of imatinib and/or cAbl inhibitors capable of efficiently crossing the hematoencephalic barrier are required to evaluate the consequences of local CNS treatment.
At present there is no treatment for patients with NPC disease. However, some agents have proved to have therapeutic effects in animals and patients with NPC disease. Substrate reduction therapy using miglustat to diminish glycolipid biosynthesis has shown efficacy in NPC mice, delaying clinical onset and neuropathological changes and improving life expectancy in 25% (60) . These results, together with the ability of miglustat to cross the blood-brain barrier (61) and the fact that this agent is currently approved for treatment of patients with type I Gaucher disease, prompted continuation of the first human trial for patients with NPC disease with encouraging results (62) . Another agent used successfully in NPC mice is the neurosteroid Allo. Adult NPC mouse brains show diminished concentration of this neurosteroid, and treating 7-day-old NPC mice with a single Allo injection protocol resulted in doubling of their life span, a substantial delay in the onset of neurological symptoms, and survival of cerebellar Purkinje cells (57) . Most of the therapeutic studies in NPC disease, including ours, have been conducted in the NIH mouse model, effectively an NPC1 knockout, which exhibits several pathological features of patients with the most severe NPC disease. This fact should be considered in translating the effects seen in mice to clinical studies.
All of these results, including ours, suggest that combined therapy with different drugs, such as earlyacting antiapoptotic agents (imatinib), miglustat, Allo (or its derivatives), and anti-inflammatory drugs could be useful in NPC treatment.
In summary, our results demonstrate that apoptosis and activation of the c-Abl/p73 pathway are early and relevant processes involved in cerebellar neuronal death in NPC mice. Also, we found that inhibition of c-Abl is useful for treating the neurodegeneration of Purkinje neurons and for ameliorating neurological symptoms in NPC mice. Greater understanding of the mechanism leading to the activation of the c-Abl/p73 system should provide better insights into the pathophysiology of NPC disease, leading to the development of expanded treatment options for the children who have this devastating disease.
